Business Context and Reporting Period
This Form 8-K is filed by Nemus Bioscience, Inc. (not Skye Bioscience, Inc.) for the reporting period of January 7, 2015. The company is incorporated in Nevada and is headquartered in Costa Mesa, California. The filing primarily reports the closing of a private placement of common stock and a change in the company's office suite.
Key Financial Metrics
The filing discloses specific transaction details regarding a capital raise but does not provide comprehensive financial statements such as revenue, operating profit, cash flow, or debt levels.
- Capital Raised: $724,989 in aggregate proceeds.
- Shares Issued: 241,663 shares of common stock.
- Price Per Share: $3.00.
- Investors: Seven accredited investors.
- Liquidity/Debt: The filing text does not provide a clear value for total debt, cash on hand, or liquidity ratios outside of the proceeds from this specific transaction.
Material Changes
The primary material change is the entry into a Material Definitive Agreement on January 7, 2015, resulting in the issuance of unregistered equity securities. Additionally, the company updated its physical address, moving from Suite 620 to Suite 1770 at 650 Town Center Drive, Costa Mesa, CA 92626.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard regulatory disclosures. The transaction was conducted under Section 4(2) of the Securities Act of 1933 and Rule 506 of Regulation D. The company has entered into a Registration Rights Agreement, agreeing to file a registration statement with the SEC within 180 days of the closing date to register the purchased shares.
Investor Verification Checklist
- Verify the company name discrepancy: The filing is for Nemus Bioscience, Inc., not Skye Bioscience, Inc.
- Confirm the status of the Registration Rights Agreement and the filing of the required registration statement within the 180-day window.
- Review the full text of the Common Stock Purchase Agreement (Exhibit 10.1) for any covenants or restrictions not detailed in the summary.
- Check subsequent filings for updated financial statements to assess the impact of the $724,989 capital raise on overall liquidity.